FWM
AKBA icon

Focused Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Focused Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-65
Closed -$81 – 235
2023
Q4 		$81 Hold
65
– – ﹤0.01% 985
2023
Q3 		$74 Hold
65
– – ﹤0.01% 997
2023
Q2 		$59 Hold
65
– – ﹤0.01% 1038
2023
Q1 		$36 Hold
65
– – ﹤0.01% 1023
2022
Q4 		$38 Hold
65
– – ﹤0.01% 1064
2022
Q3 		$0 Hold
65
– – ﹤0.01% 936
2022
Q2 		$0 Hold
65
– – ﹤0.01% 915
2022
Q1 		$0 Hold
65
– – ﹤0.01% 980
2021
Q4 		$0 Hold
65
– – ﹤0.01% 971
2021
Q3 		$0 Hold
65
– – ﹤0.01% 985
2021
Q2 		$0 Buy
+65
New +$219 ﹤0.01% 923

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Focused Wealth Management's AKBA Position: Q1 2024 in Review

Focused Wealth Management sold out of Akebia Therapeutics (AKBA) in Q1 2024, closing a stake of 65 shares — an estimated $81 sold.

Focused Wealth Management first reported a position in AKBA in Q2 2021 and held it in 11 quarters. The position peaked at $81 in Q4 2023. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

  • Focused Wealth Management reported no remaining Akebia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 65 Akebia Therapeutics shares in Q1 2024, an estimated $81.
  • Focused Wealth Management first reported a position in Akebia Therapeutics in Q2 2021 and held it in 11 quarters.
  • Focused Wealth Management's Akebia Therapeutics position peaked at $81 in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.